Vancouver-based CytoDyn Inc., a biotechnology company developing the drug leronlimab, has a new interim CEO, Dr. Jacob Lalezari.
Lalezari, who got his medical degree from the University of Pennsylvania, has been on the company’s advisory board for several years. He also served as interim chief medical officer in 2020. He will be focusing on the company’s short-term clinical development and fundraising, and leading CytoDyn’s corporate and product development, according to a statement the company released Tuesday.
Antonio Migliarese, who had been serving as interim president since May 2023, in addition to chief financial officer, will resume his previous role as chief financial officer.
